Literature DB >> 19265659

Cancer stem cells: controversial or just misunderstood?

Craig T Jordan1.   

Abstract

While a broad range of expertise has recently come to bear on the intriguing topic of "cancer stem cells," the overall relevance of stem cells as they relate to cancer remains in dispute. In this commentary, underlying points of contention are described with the aim of defining focal points for discussion and future consideration.

Entities:  

Mesh：

Year:  2009        PMID： 19265659      PMCID： PMC2871155          DOI： 10.1016/j.stem.2009.02.003

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  14 in total

1.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

Authors:  Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl
Journal:  Cancer Res       Date:  2006-09-21       Impact factor: 12.701

2.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

3.  Survival of acute myeloid leukemia cells requires PI3 kinase activation.

Authors:  Qing Xu; Serge-Emile Simpson; Timothy J Scialla; Adam Bagg; Martin Carroll
Journal:  Blood       Date:  2003-04-17       Impact factor: 22.113

4.  MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia.

Authors:  N Feller; M A van der Pol; A van Stijn; G W D Weijers; A H Westra; B W Evertse; G J Ossenkoppele; G J Schuurhuis
Journal:  Leukemia       Date:  2004-08       Impact factor: 11.528

5.  Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.

Authors:  David C Taussig; Farideh Miraki-Moud; Fernando Anjos-Afonso; Daniel J Pearce; Kirsty Allen; Christopher Ridler; Debra Lillington; Heather Oakervee; Jamie Cavenagh; Samir G Agrawal; T Andrew Lister; John G Gribben; Dominique Bonnet
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

6.  Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm.

Authors:  Jean C Y Wang
Journal:  Cell Stem Cell       Date:  2007-11       Impact factor: 24.633

7.  Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma.

Authors:  Craig D Peacock; Qiuju Wang; Gregory S Gesell; Ian M Corcoran-Schwartz; Evan Jones; Jynho Kim; Wendy L Devereux; Jonathan T Rhodes; Carol A Huff; Philip A Beachy; D Neil Watkins; William Matsui
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-27       Impact factor: 11.205

Review 8.  Is tumor growth sustained by rare cancer stem cells or dominant clones?

Authors:  Jerry M Adams; Andreas Strasser
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

9.  Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells.

Authors:  Andrea Viale; Francesca De Franco; Annette Orleth; Valeria Cambiaghi; Virginia Giuliani; Daniela Bossi; Chiara Ronchini; Simona Ronzoni; Ivan Muradore; Silvia Monestiroli; Alberto Gobbi; Myriam Alcalay; Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nature       Date:  2009-01-01       Impact factor: 49.962

10.  Efficient tumour formation by single human melanoma cells.

Authors:  Elsa Quintana; Mark Shackleton; Michael S Sabel; Douglas R Fullen; Timothy M Johnson; Sean J Morrison
Journal:  Nature       Date:  2008-12-04       Impact factor: 49.962
View more
  68 in total

1.  Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML.

Authors:  Kenneth D Gibbs; Astraea Jager; Oliver Crespo; Yury Goltsev; Angelica Trejo; Chase E Richard; Garry P Nolan
Journal:  Cell Stem Cell       Date:  2012-02-03       Impact factor: 24.633

Review 2.  The influence of subclonal resistance mutations on targeted cancer therapy.

Authors:  Michael W Schmitt; Lawrence A Loeb; Jesse J Salk
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

Review 3.  Cancer stem cells: a new framework for the design of tumor therapies.

Authors:  Boyan K Garvalov; Till Acker
Journal:  J Mol Med (Berl)       Date:  2010-10-02       Impact factor: 4.599

Review 4.  Oncolytic virus as a cancer stem cell killer: progress and challenges.

Authors:  Jingzhen Ding
Journal:  Stem Cell Investig       Date:  2014-12-28

Review 5.  TGF-β signaling and its targeting for glioma treatment.

Authors:  Jianfeng Han; Christopher A Alvarez-Breckenridge; Qi-En Wang; Jianhua Yu
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

Review 6.  Ethical development of stem-cell-based interventions.

Authors:  Amanda MacPherson; Jonathan Kimmelman
Journal:  Nat Med       Date:  2019-07-03       Impact factor: 53.440

Review 7.  Cervical cancer stem cells: opportunities and challenges.

Authors:  Ravindresh Chhabra
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-07       Impact factor: 4.553

Review 8.  IL-32θ: a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity.

Authors:  Muhammad Babar Khawar; Maryam Mukhtar; Muddasir Hassan Abbasi; Nadeem Sheikh
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

9.  Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.

Authors:  Ryan Morrison; Stephen M Schleicher; Yunguang Sun; Kenneth J Niermann; Sungjune Kim; Daniel E Spratt; Christine H Chung; Bo Lu
Journal:  J Oncol       Date:  2010-10-12       Impact factor: 4.375

10.  Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells.

Authors:  Ines Herrmann; Patrick A Baeuerle; Matthias Friedrich; Alexander Murr; Susanne Filusch; Dominik Rüttinger; Mariam W Majdoub; Sherven Sharma; Peter Kufer; Tobias Raum; Markus Münz
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.